Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives - CIRI - Physiopathologie et biothérapies des infections muqueuses
Article Dans Une Revue The Lancet Gastroenterology & Hepatology Année : 2023

Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives

Résumé

Therapeutic drug monitoring (TDM) has emerged as a useful tool for optimizing biologics, and in particular anti-tumor necrosis factor (anti-TNF) therapy, in both inflammatory bowel disease (IBD) and other immune-mediated inflammatory diseases such as rheumatoid arthritis and psoriasis. However, there are still some challenges hindering the widespread implementation of TDM in clinical practice. These barriers include identification of the optimal drug concentration to target, the lag time between sampling and results, and the proper interpretation of antidrug antibody titers among different assays. Solutions to overcome these barriers include the harmonization of TDM assays and the use of point-of-care testing. Other unmet needs include well-designed prospective studies and randomized controlled trials focusing on proactive TDM particularly during induction therapy. Future studies should also investigate the utility of TDM in Papamichael et al.

Mots clés

Lilly, Pfizer, Prometheus Biosciences, Seres Therapeutics, Shire, Takeda, Theravance Biopharma consulting fees from Abbvie, Abivax, Admirx, Alfasigma, Alimentiv (previously Robarts Clinical Trials, owned by Alimentiv Health Trust), Alivio Therapeutics, Allakos, Amgen, Applied Molecular Transport, Arena Pharmaceuticals, Bausch Health (Salix), Beigene, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Meyers Squibb, Celgene, Celltrion, Cellularity, Cosmo Pharmaceuticals, Escalier Biosciences, Equillium, Forbion, Genentech/Roche, Gilead Sciences, Glenmark Pharmaceuticals, Gossamer Bio, Immunic (Vital Therapies), Index Pharmaceuticals, Intact Therapeutics, Janssen, Kyverna Therapeutics, Landos Biopharma, Lilly, Oppilan Pharma, Otsuka, Pandion Therapeutics, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonists Therapeutics, Provention Bio, Reistone Biopharma, Seres Therapeutics, Shanghai Pharma Biotherapeutics, Shire, Shoreline Biosciences, Sublimity Therapeutics, Surrozen, Takeda, Theravance Biopharma, Thetis inflammatory bowel disease Crohn's disease ulcerative colitis therapeutic drug monitoring infliximab adalimumab vedolizumab ustekinumab pharmacokinetic dashboards Trough Concentration Adapted Infliximab Treatment TAILORIX: A Study investigating Tailored Treatment With Infliximab for Active Crohn's Disease PRECISION: Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab PAILOT: Pediatric Crohn's Disease Adalimumab Level-based Optimization Treatment RCT: randomized controlled trial IBD: inflammatory bowel disease N/A: not applicable CD: Crohn's disease UC: ulcerative colitis CS: corticosteroids TDM: therapeutic drug monitoring TC: trough concentration PK: pharmacokinetic CDAI: Crohn's disease activity index IFX: infliximab ADM: adalimumab Lilly, Pfizer, Prometheus Biosciences, Seres Therapeutics, Shire, Takeda, Theravance Biopharma consulting fees from Abbvie, Abivax, Admirx, Alfasigma, Alimentiv (previously Robarts Clinical Trials, owned by Alimentiv Health Trust), Alivio Therapeutics, Allakos, Amgen, Applied Molecular Transport, Arena Pharmaceuticals, Bausch Health (Salix), Beigene, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Meyers Squibb, Celgene, Celltrion, Cellularity, Cosmo Pharmaceuticals, Escalier Biosciences, Equillium, Forbion, Genentech/Roche, Gilead Sciences, Glenmark Pharmaceuticals, Gossamer Bio, Immunic (Vital Therapies), Index Pharmaceuticals, Intact Therapeutics, Janssen, Kyverna Therapeutics, Landos Biopharma, Lilly, Oppilan Pharma, Otsuka, Pandion Therapeutics, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonists Therapeutics, Provention Bio, Reistone Biopharma, Seres Therapeutics, Shanghai Pharma Biotherapeutics, Shire, Shoreline Biosciences, Sublimity Therapeutics, Surrozen, Takeda, Theravance Biopharma, Thetis inflammatory bowel disease Crohn's disease ulcerative colitis therapeutic drug monitoring infliximab adalimumab vedolizumab ustekinumab pharmacokinetic dashboards Trough Concentration Adapted Infliximab Treatment TAILORIX: A Study investigating Tailored Treatment With Infliximab for Active Crohn's Disease PRECISION: Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab PAILOT: Pediatric Crohn's Disease Adalimumab Level-based Optimization Treatment RCT: randomized controlled trial IBD: inflammatory bowel disease N/A: not applicable CD: Crohn's disease UC: ulcerative colitis CS: corticosteroids TDM: therapeutic drug monitoring TC: trough concentration PK: pharmacokinetic CDAI: Crohn's disease activity index IFX: infliximab ADM: adalimumab
Fichier principal
Vignette du fichier
nihms-1856492.pdf (615.09 Ko) Télécharger le fichier
Origine Accord explicite pour ce dépôt

Dates et versions

hal-04872944 , version 1 (08-01-2025)

Identifiants

Citer

Konstantinos Papamichael, Waqqas Afif, David Drobne, Marla C Dubinsky, Marc Ferrante, et al.. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. The Lancet Gastroenterology & Hepatology, 2023, 7, pp.171 - 185. ⟨10.1016/s2468-1253(21)00223-5⟩. ⟨hal-04872944⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More